Validated late-onset AD risk insights
Comprehensive WGS analyzes the variants behind the three common APOE alleles (ε2, ε3, ε4) to identify which of the six common genotypes your patient carries.
Assess inherited Alzheimer’s disease risk
Available only as an add-on to Curated Screen, APOE genotyping uses whole-genome sequencing (WGS) to assess inherited risk for late-onset Alzheimer’s disease (AD) and, when applicable, related cardiovascular and lipid considerations.
What APOE Add-On Does
Alzheimer's risk insights from whole-genome sequencing
The APOE Add-On uses WGS to characterize the variants that define the three common alleles (ε2, ε3, ε4), helping identify which of six common genotypes your patient has and informing late-onset AD risk relative to the population baseline.
Add-on or re-requisition
The APOE Add-On draws on the same whole-genome data as Curated Screen, producing a focused, standalone report without requiring a separate test order or sample.
Inform proactive care
An APOE result can inform lipid screening and risk management, guide future treatment eligibility discussions, and prompt personal, family, and care planning conversations.
Risk categories reported
Six genotypes, three clear risk categories
Three common APOE alleles produce six genotypes. Each report assigns one of three risk categories.
| Genotype | Population frequency | Lifetime AD risk† | Risk category |
|---|---|---|---|
| ε2/ε2 | <1% | Lower than average | Decreased |
| ε2/ε3 | ~10-15% | Slightly lower than average | Decreased |
| ε3/ε3 | ~60% (most common) | Population baseline (~10-15%)1,2 | Average |
| ε2/ε4 | ~2% | Slightly higher than average | Increased |
| ε3/ε4 | ~20-25% | ~20-25% by age 853 | Increased |
| ε4/ε4 | ~2-3% | ~50-60% by age 853 | Increased |
†Risk estimates are derived primarily from studies of individuals of European ancestry and vary by sex and age horizon; both risk magnitude and allele frequency differ across ancestral populations.
Ordering
Add it to a new order, or re-query an existing genome
Patient* (aged 18+)
New patient
Ordered alongside Curated Screen at no additional cost
Existing Curated Screen patient
Ordered as a re-requisition - no new patient sample required
WGS and analysis
New patient
APOE genotyped from the Curated Screen dataset
Existing Curated Screen patient
Existing dataset re-queried for APOE genotype
Report
New patient
Standalone APOE report delivered in ~5-6 weeks, separately from the Curated Screen report
Existing Curated Screen patient
Standalone APOE report delivered in ~1 week
*Intended for asymptomatic adults; not diagnostic. Does not assess early-onset AD genes (APP, PSEN1, PSEN2).
Important test considerations
- APOE Add-On must be actively selected at ordering; it is never included by default. If the Curated Screen order is cancelled, the APOE add-on is cancelled with it.
- Standard Atlas monogenic consent applies; no additional consent form is required.
- Risk estimates are derived primarily from European-ancestry cohorts and may over- or understate risk in other populations.
Learn more
APOE Add-On Resources
- Goldman JS, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597–605. doi:10.1097/GIM.0b013e31821d69b8
- Liu CC, et al. Nat Rev Neurol. 2013;9(2):106–118. doi:10.1038/nrneurol.2012.263
- Genin E, et al. Mol Psychiatry. 2011;16(9):903–907. doi:10.1038/mp.2011.52
This test was developed, and its performance characteristics determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologists (CAP) accredited to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data and with the availability of genetic counseling when appropriate.
Focused APOE insight from an Atlas genome.
We're here at every step - from ordering and sample collection to interpreting results with your patients.